By Sherri Oslick --
On Tuesday, Teva Pharmaceuticals and Dr. Reddy's Laboratories filed a joint stipulation of dismissal in their pending lawsuit over generic sertraline hydrochloride (the API in Pfizer's Zoloft®, used to treat depression). The suit, originally filed on February 1, 2007 in the District Court of New Jersey, was dismissed without prejudice, with the stipulation of dismissal noting that Dr. Reddy's is not selling, and has 
no current intention to sell, generic Zoloft® to anyone other than Teva, and that Dr. Reddy's will provide Teva with 30 days advance notice of any importation, sale, offer to sell, or use of sertraline hydrochloride finished product or API.
The settlement of Teva's suit against Dr. Reddy's ends just one of many pending actions filed by Teva earlier this year surrounding the manufacture of generic Zoloft®. Information on these actions can be found in our previous reports of February 25, March 4, April 15, and June 3, 2007. At issue in each of these cases, including the action against Dr. Reddy's, are four U.S. patents: 6,600,073 ("Methods for Preparation of Sertraline Hydrochloride Polymorphs," issued July 29, 2003), 6,500,987 ("Sertraline Hydrochloride Polymorphs," issued December 31, 2002), 6,495,721 ("Sertraline Hydrochloride Form II and Methods for the Preparation Thereof," issued December 17, 2002), and 6,897,340 ("Processes for Preparation of Polymorphic Form II of Sertraline Hydrochloride," issued May 24, 2005), all directed to methods of manufacturing crystalline forms of sertraline hydrochloride.
Comments